ABVC Biopharma Files 8-K/A Amendment
Ticker: ABVC · Form: 8-K/A · Filed: Jul 18, 2025 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | Jul 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement, equity-securities
TL;DR
ABVC Bio filed an 8-K/A amendment on July 18, 2025, updating material agreements and financials from Feb 8, 2024.
AI Summary
ABVC Biopharma, Inc. filed an amendment (8-K/A) on July 18, 2025, to a previous filing dated February 8, 2024. This amendment pertains to the entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits. The company, formerly known as American BriVision (Holding) Corp, is incorporated in Nevada and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides updated information regarding material agreements and financial disclosures for ABVC Biopharma, which could impact investor understanding of the company's recent activities and financial health.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings can indicate a need for clarification or correction of previously disclosed material information, suggesting potential complexities or changes in the company's reported events.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- July 18, 2025 (date) — Date of Report
- February 8, 2024 (date) — Earliest Event Reported
- American BriVision (Holding) Corp (company) — Former Company Name
- Nevada (jurisdiction) — State of Incorporation
FAQ
What specific material definitive agreement is being amended or clarified in this 8-K/A filing?
The filing indicates an amendment related to 'Entry into a Material Definitive Agreement' but does not specify the agreement's details within the provided text.
What is the nature of the 'Unregistered Sales of Equity Securities' mentioned in the filing?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, but the specific details of these sales are not provided in the excerpt.
Why is ABVC Biopharma filing an amendment (8-K/A) to its previous report?
The 8-K/A filing is an amendment to a previous report, suggesting a need to update or correct information previously filed on February 8, 2024, concerning material agreements, equity sales, or financial statements.
What is the significance of the 'Date as of Change' being July 18, 2025?
The 'Date as of Change' of July 18, 2025, indicates the date on which the amendment to the filing was made or became effective.
What industry does ABVC Biopharma, Inc. operate in?
ABVC Biopharma, Inc. operates in the 'Pharmaceutical Preparations' industry, with Standard Industrial Classification code 2834.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on July 18, 2025 regarding ABVC BIOPHARMA, INC. (ABVC).